ICU Medical, Inc. (NASDAQ:ICUI) Receives $181.75 Consensus Price Target from Brokerages

Shares of ICU Medical, Inc. (NASDAQ:ICUI) have earned an average recommendation of “Moderate Buy” from the six research firms that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, three have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $181.75.

ICUI has been the topic of a number of analyst reports. Wall Street Zen lowered ICU Medical from a “buy” rating to a “hold” rating in a report on Saturday, November 15th. Raymond James Financial decreased their price target on ICU Medical from $187.00 to $180.00 and set a “strong-buy” rating on the stock in a research note on Friday, August 8th. KeyCorp increased their price objective on ICU Medical from $173.00 to $175.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of ICU Medical in a report on Wednesday, October 8th. Finally, Piper Sandler boosted their target price on shares of ICU Medical from $153.00 to $172.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th.

Insider Transactions at ICU Medical

In other ICU Medical news, VP Virginia Ruth Sanzone sold 930 shares of the company’s stock in a transaction dated Tuesday, November 11th. The shares were sold at an average price of $142.34, for a total transaction of $132,376.20. Following the transaction, the vice president directly owned 5,456 shares in the company, valued at approximately $776,607.04. This represents a 14.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Elisha W. Finney sold 1,285 shares of ICU Medical stock in a transaction that occurred on Tuesday, November 11th. The shares were sold at an average price of $140.42, for a total transaction of $180,439.70. Following the sale, the director owned 3,995 shares of the company’s stock, valued at approximately $560,977.90. The trade was a 24.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 1.50% of the stock is currently owned by insiders.

Institutional Trading of ICU Medical

Several large investors have recently bought and sold shares of the company. Millennium Management LLC raised its stake in shares of ICU Medical by 173.4% during the 3rd quarter. Millennium Management LLC now owns 1,089,017 shares of the medical instruments supplier’s stock worth $130,638,000 after buying an additional 690,694 shares during the last quarter. State Street Corp raised its position in ICU Medical by 3.2% during the second quarter. State Street Corp now owns 927,799 shares of the medical instruments supplier’s stock worth $122,609,000 after acquiring an additional 28,491 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of ICU Medical by 16.9% in the third quarter. Dimensional Fund Advisors LP now owns 872,993 shares of the medical instruments supplier’s stock valued at $104,718,000 after purchasing an additional 126,072 shares in the last quarter. Ameriprise Financial Inc. lifted its holdings in shares of ICU Medical by 34.0% in the third quarter. Ameriprise Financial Inc. now owns 803,542 shares of the medical instruments supplier’s stock valued at $96,393,000 after purchasing an additional 203,746 shares in the last quarter. Finally, Schroder Investment Management Group grew its position in shares of ICU Medical by 25.2% in the third quarter. Schroder Investment Management Group now owns 796,704 shares of the medical instruments supplier’s stock valued at $93,246,000 after purchasing an additional 160,380 shares during the last quarter. Institutional investors and hedge funds own 96.10% of the company’s stock.

ICU Medical Price Performance

Shares of NASDAQ ICUI opened at $148.43 on Friday. The stock has a fifty day moving average price of $127.51 and a 200 day moving average price of $128.58. ICU Medical has a 1-year low of $107.00 and a 1-year high of $175.51. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.44 and a quick ratio of 1.17. The company has a market cap of $3.66 billion, a PE ratio of -97.65 and a beta of 0.83.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $2.03 EPS for the quarter, topping analysts’ consensus estimates of $1.43 by $0.60. The company had revenue of $533.30 million during the quarter, compared to the consensus estimate of $511.46 million. ICU Medical had a negative net margin of 1.56% and a positive return on equity of 7.24%. ICU Medical’s quarterly revenue was down 8.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.59 EPS. ICU Medical has set its FY 2025 guidance at 7.350-7.650 EPS. Sell-side analysts forecast that ICU Medical will post 4.11 EPS for the current year.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.